

Corp. Off.: 502, Kanakia Atrium - 2,
Next to Courtyard Marriott Hotel,
Andheri Kurla Road, Andheri (East),
Mumbai - 400 093 (India)
Ph.: + 91 22 61933100 Fax : +91 22 61933114

29th May, 2018

BSE Limited

Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai-400001

National Stock Exchange of India Ltd.

Exchange Plaza, C-1, Block G
Bandra Kurla Complex
Bandra (E), Mumbai-400051

Scrip Code: **533543**

Symbol: **BROOKS**

Sub: Disclosure under Regulation 30 & Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015

Dear Sirs,

This has in reference to the regulation mentioned above:

We hereby inform you that the Board of Directors at its meeting held today 29th May, 2018 has, inter alia, approved the Audited Financial Results of the Company for Quarter & Year ended 31st March, 2018.

Enclosed please find herewith the following

1. Audited financial results of the Company for the financial year ended 31st March, 2018 and the financial results of the Company in respect of the fourth quarter of FY 2017-18.
2. Statement of Assets and Liabilities.
3. The Auditors Report,
4. Declaration from the Company for Audit Report is of 'Unmodified Opinion',

The aforesaid result and report are attached for your record.

Thanking You,

Yours faithfully


For **BROOKS LABORATORIES LIMITED**



(Jyoti Sancheti)

Company Secretary cum Compliance Officer

Encl.: As above



BROOKS LABORATORIES LIMITED

Regd Office: Village Kishanpura, Nalagarh Road, Baddi, Dist. Solan H.P.-174101

CIN NO: L24232HP2002PLC000267

Tel No : +91 1795 654001/02/03, Fax No :+91 1795 236939, E-mail : investors@brookslabs.net,

Website: www.brookslabs.net

Audited Financial Results for the Quarter and Year Ended March 31, 2018

(Rs. in Lacs)

Particulars	Quarter Ended			Year Ended	Year ended
	31.03.2018	31.12.2017	31.03.2017	31.03.2018	31.03.2017
	(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
1 Income					
(a) Revenue from Operations	1,451.61	2,087.50	1,627.96	5,690.42	6,484.30
(b) Other income	11.85	2.27	4.92	24.02	12.27
Total Income	1,463.46	2,089.77	1,632.88	5,714.44	6,496.57
2 Expenses					
(a) Cost of materials consumed	1,057.61	1,516.16	974.39	4,084.63	3,664.91
(b) Changes in inventories of finished goods & work-in-progress.	(125.95)	14.57	63.32	(147.03)	1.35
(c) Excise duty on sale of goods	-	-	195.70	119.27	730.32
(d) Employee benefits expense	331.13	305.68	238.31	1,180.73	825.24
(e) Finance costs	72.42	71.38	32.53	244.02	100.94
(f) Depreciation and amortisation expense	161.38	164.32	69.81	644.51	167.20
(g) Other Expenses	362.76	351.05	226.40	1,341.74	758.32
Total expenses	1,859.34	2,423.16	1,800.46	7,467.86	6,248.28
3 Profit / (Loss) before exceptional items and tax (1-2)	(395.88)	(333.39)	(167.58)	(1,753.42)	248.29
4 Exceptional items	-	-	-	-	-
5 Profit / (Loss) from ordinary activities before tax (3-4)	(395.88)	(333.39)	(167.58)	(1,753.42)	248.29
6 Tax expense					
- Current tax	-	-	(122.75)	-	4.24
- Deferred tax	(169.65)	(71.13)	73.23	(375.09)	73.04
- Tax of earlier years	-	-	-	2.95	4.32
7 Net Profit / (Loss) for the period (5-6)	(226.23)	(262.26)	(118.05)	(1,381.28)	166.69
8 Other Comprehensive Income					
- Items that will not be reclassified to Profit or loss	0.78	0.01	8.56	0.81	10.17
Total Other Comprehensive Income (Net of tax)	0.78	0.01	8.56	0.81	10.17
9 Total Comprehensive Income (7+8)	(225.45)	(262.25)	(109.49)	(1,380.47)	176.86
10 Paid-up equity share capital (Face Value Rs.10/- per share)	1,618.64	1,618.64	1,618.64	1,618.64	1,618.64
11 Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	11,209.05	11,209.05	11,032.18	11,209.05	11,032.18
12 Earnings per share of Rs.10/- each (not annualised):					
(a) Basic -in Rs.	(1.40)	(1.62)	(0.73)	(8.53)	1.03
(b) Diluted- in Rs.	(1.40)	(1.62)	(0.73)	(8.53)	1.03

For Brooks Laboratories Ltd.


Managing Director
 DIN No. 02000634

Notes to the Financial Results:-

1. The above audited Financial Results of the Company for the quarter and year ended March 31, 2018 have been reviewed by the Audit committee and taken on record by the Board of Directors at its meeting held on May 29, 2018.
2. The financial results have been prepared in accordance with Indian Accounting Standards ("Ind AS") as notified under the Companies (Indian Accounting Standards) Rules, 2015 as specified in section 113 of the Companies Act, 2013.
3. The Company has adopted Indian Accounting Standards (Ind AS) w.e.f. April 1, 2017 and accordingly the above financial results have been prepared in accordance with the recognition and measurement principles as laid down in the Ind AS as prescribed under section 113 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. The date of transition to Ind AS is 1st April, 2016.
4. The Ind-AS compliant corresponding figures in the previous quarters and year have been subject to review or audit by the statutory auditors.
5. Consequent to the introduction of Goods and Services Tax (GST) with effect from July, 1, 2017, Central Excise Duty, Value Added Tax (VAT), etc., have been replaced by GST. In accordance with Ind AS-18 "Revenue" and Schedule-III of Companies Act, 2013, GST is not included in total income from operation for quarter ended post July 1st, 2017. However, for the quarter ended June 30th, 2017 and earlier comparative periods, excise duty is included in revenue from operations, hence not comparable.
6. The Company is mainly engaged in the business of "Pharmaceutical Formulations" and there is no other reportable business segment. As the Company's business actually falls within a single primary business segment, the disclosure requirements of Ind-AS – 108 in this regard are not applicable.

For Brooks Laboratories Ltd.


Managing Director
DIN NO. 02000634

7. Reconciliation of Net Profit and Total Comprehensive Income on account of transition from the previous Indian GAAP to Ind-AS for the Quarter and Financial Year ended March, 31, 2017 is as under:

(Rs. In Lakhs)


Sr. No.	Particulars	For the Quarter ended March 31, 2017	For the Year ended March 31, 2017
	Net Profit as per Indian GAAP	(88.41)	195.65
	Benefit / (Charge)		
I	Actuarial Loss on Defined Benefit Plans reclassified to Other Comprehensive Income		
II	Provision for expected credit loss	(40.56)	(53.53)
III	Deferred Tax impact on above adjustments	3.05	19.12
IV	Increase of Gratuity Expense as per Ind AS	(1.89)	(4.30)
V	Deferred tax on Indexed cost of Land	9.75	9.75
	Net Profit for the Quarter (as per Ind-AS)	(118.06)	166.69
	Other Comprehensive Income		
	Actuarial Loss on Defined Benefit Plans (net of tax)	8.56	10.17
	Total Profit including Comprehensive Income	(109.50)	176.86

8. The reconciliation of equity between previous Indian GAAP and Ind AS is as under :

Sr. No.	Particulars	Year ended March 31, 2017
	Equity as per previous GAAP	12,400.66
	Benefit / (Charge)	
	Provision for expected credit loss	(307.39)
I	Increase of Gratuity Expense as per Ind AS	5.87
II	Deferred Tax impact on above adjustments	103.06
III	Gains on Revaluation of Land	735.84
IV	Deferred tax on Indexed cost of Land	(110.33)
	Equity as per Ind-AS	12,827.69

9. The figures of the last quarter ended March, 31, 2018 and March, 31, 2017 are the balancing figures between audited figures in respect of full financial year and the published year to date figures up to the third quarter of the relevant financial year.
10. Comparative financial information of the previous quarter and financial year have been regrouped and reclassified, wherever necessary, to correspond to the figures of the current period presentation.

For BROOKS LABORATORIES LIMITED



Rajesh Mahajan
Managing Director
(DIN 02000634)

Dated: - 29th May, 2018

Place: - Mumbai

BROOKS LABORATORIES LIMITED**Statement of Asset and Liabilities as at March 31, 2018**

(₹ in lakhs)

Particulars	As at 31 March 2018	As at 31 March 2017
ASSETS		
Non-current assets		
Property, Plant and Equipment	12,401.04	12,531.45
Capital work-in-progress	52.16	-
Investment Property	63.35	63.35
<u>Financial assets</u>		
Investments	2.00	2.00
Other financial assets	140.63	164.63
Deferred tax assets (net)	1,073.97	699.19
Other non-current assets	129.57	402.18
Income tax assets (net)	438.92	363.54
Total non-current assets	14,301.64	14,226.34
Current assets		
Inventories	1,140.91	769.89
<u>Financial assets</u>		
Trade receivables	1,018.24	1,068.88
Cash and cash equivalents	64.55	13.97
Other bank balances	131.95	169.71
Loans	1.20	2.05
Other financial assets	32.22	25.94
Other current assets	575.75	136.22
Total current assets	2,964.82	2,186.66
TOTAL ASSETS	17,266.46	16,413.00
EQUITY AND LIABILITIES		
Equity		
Share capital	1,618.64	1,618.64
Other equity	9,828.59	11,209.05
Total equity	11,447.23	12,827.69
Liabilities		
Non-current liabilities		
<u>Financial liabilities</u>		
Borrowings	1,725.84	1,072.59
Provisions	108.42	86.64
Total non-current liabilities	1,834.26	1,159.23
Current liabilities		
<u>Financial liabilities</u>		
Borrowings	854.44	217.55
Trade payables	2,649.55	1,836.40
Other financial liabilities	353.98	289.88
Other current liabilities	92.49	69.74
Provisions	34.51	12.51
Total current liabilities	3,984.97	2,426.08
TOTAL EQUITY AND LIABILITIES	17,266.46	16,413.00

For Brooks Laboratories Ltd.



Managing Director

DIN No. 02000634

SGCO & Co. LLP

Chartered Accountants

INDEPENDENT AUDITOR'S REPORT

To The Board of Directors of Brooks Laboratories Limited

1. We have audited the Financial Results ("the Results") of **Brooks Laboratories Limited** ("the Company") for the year ended March 31, 2018 included in the accompanying Statement of Financial Results ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016. The Results, which are the responsibility of the Company's Management and approved by the Board of Directors, have been compiled from the related financial statements which have been prepared in accordance with the Indian Accounting Standards, prescribed under section 133 of the Companies Act, 2013, read with the relevant rules issued thereunder ('Ind AS') and other accounting principles generally accepted in India. Our responsibility is to express an opinion on the Results based on our audit of the financial statements.
2. We conducted our audit in accordance with the Standards on Auditing issued by the Institute of Chartered Accountants of India. Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the Results are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the Results. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the Results, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the Company's preparation and fair presentation of the Results in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the management, as well as evaluating the overall presentation of the Results.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

4A, Kaledonia-HDIL,
2nd Floor, Sahar Road,
Near Andheri Station,
Andheri (East),
Mumbai - 400 069. India

Tel.: +91 22 6625 6363
Fax: +91 22 6625 6364
E-mail: info@sgco.co.in
www.sgco.co.in



Mumbai • Bengaluru

SGCO & Co. LLP


Chartered Accountants

3. In our opinion and to the best of our information and according to the explanations given to us, the Results
 - a. are presented in accordance with the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016; and
 - b. give a true and fair view in conformity with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, of the net loss, total comprehensive loss and other financial information of the Company for the year ended March 31, 2018.
4. The Statement includes the results for the Quarter ended March 31, 2018 being the balancing figure between the audited figures in respect of full financial year and published year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

For S G C O & Co. LLP

Chartered Accountants

Firm Registration No. : 112081W/W100184


Suresh Murarka

Partner

Mem. No. : 044739



Place: Mumbai

Date: 29th May, 2018

Corp. Off.: 502, Kanakia Atrium - 2,
Next to Courtyard Marriott Hotel,
Andheri Kurla Road, Andheri (East),
Mumbai - 400 093 (India)
Ph.: + 91 22 61933100 Fax : +91 22 61933114

29th May, 2018

BSE Limited

Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai-400001

National Stock Exchange of India Ltd.

Exchange Plaza, C-1, Block G
Bandra Kurla Complex
Bandra (E), Mumbai-400051

Scip Code: **533543**

Symbol: **BROOKS**

Sub: Declaration by the Company for Auditors Unmodified opinion on the Audited Financials Results for the year ended 2017-18

Dear Sirs,

This has reference to the SEBI Circular No. CIR/CFD/CMD/56/2016 dated 27.05.2016 regarding disclosure of the Impact of Audit Qualifications by the Listed Companies.

We hereby declare that the Audit Report for the Annual Audited Financial Results for the year ended 31.03.2018 is of '**Unmodified Opinion**'.

Kindly take the same on record.

Thanking You,

Yours faithfully

For **BROOKS LABORATORIES LIMITED**



(Rajesh Mahajan)

Managing Director

DIN No.: 02000634